InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (16 ops.)
Discover the detailed record of transactions filed by UBS Oncology Impact Fund L.P.. Insider active across 1 companies, notably Cullinan Oncology, Inc.. Aggregated, 16 reports have been recorded. Total volume traded: €5.3m. The latest transaction was filed on 16 September 2021 — Cession. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations16 total
€77,1483,124 shares@ €24.69520.0080% mcap2.9% of flow
Common Stock
SEC:0001209191-21-056914·
€77,1483,124 shares@ €24.69520.0080% mcap1.5% of flow
Common Stock
SEC:0001209191-21-056914:0·
€175,5897,106 shares@ €24.70990.018% mcap6.6% of flow
Common Stock
SEC:0001209191-21-056411·
€175,5897,106 shares@ €24.70990.018% mcap3.3% of flow
Common Stock
SEC:0001209191-21-056411:0·
€340,68213,727 shares@ €24.81840.035% mcap12.8% of flow
Common Stock
SEC:0001209191-21-055726·
€340,68213,727 shares@ €24.81840.035% mcap6.4% of flow
Common Stock
SEC:0001209191-21-055726:0·
€317,29712,731 shares@ €24.92320.033% mcap11.9% of flow
Common Stock
SEC:0001209191-21-055203·
€317,29712,731 shares@ €24.92320.033% mcap6.0% of flow
Common Stock
SEC:0001209191-21-055203:0·
€32,0211,285 shares@ €24.9190.0033% mcap1.2% of flow
Common Stock
SEC:0001209191-21-054518·
€32,0211,285 shares@ €24.9190.0033% mcap0.6% of flow
Common Stock
SEC:0001209191-21-054518:0·
€330,50513,357 shares@ €24.7440.034% mcap12.4% of flow
Common Stock
SEC:0001209191-21-054093·
€330,50513,357 shares@ €24.7440.034% mcap6.2% of flow
Common Stock
SEC:0001209191-21-054093:0·
€1m53,359 shares@ €24.7860.14% mcap49.8% of flow
Common Stock
SEC:0001209191-21-053380·
€1m53,359 shares@ €24.7860.14% mcap24.9% of flow
Common Stock
SEC:0001209191-21-053380:0·
€62,0992,510 shares@ €24.74050.0064% mcap2.3% of flow
Common Stock
SEC:0001209191-21-051148·
€62,0992,510 shares@ €24.74050.0064% mcap1.2% of flow
Common Stock
SEC:0001209191-21-051148:0·
16 of 16 declarations
About UBS Oncology Impact Fund L.P.
UBS Oncology Impact Fund L.P. is an investor in Cullinan Oncology, Inc.
